Navigation Links
MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
Date:5/21/2013

ROCKVILLE, Md., May 21, 2013 /PRNewswire/ -- MacroGenics, Inc. today announced that an abstract titled, "Phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in patients with advanced solid tumors expressing the HER2 oncoprotein," will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology during the Developmental Therapeutics - Immunotherapy Oral Abstract Session on Monday, June 3 at 4:15 – 4:30 PM.  The presentation will describe the results of a first-in-human study of MacroGenics' next-generation anti-HER2 monoclonal antibody, margetuximab, which is being developed to treat HER2-expressing tumors.  

MacroGenics has optimized the Fc region of margetuximab to increase cancer cell killing via Antibody-Dependent Cell-mediated Cytotoxicity (ADCC).  Margetuximab also has shown improved control of tumor growth in human tumor xenograft models in mice as compared to that of anti-HER2 antibodies with a wild type Fc region.  A development goal for margetuximab is to enable the treatment of a broader population of patients than those eligible for treatment with current HER2-targeted therapies.

MacroGenics also announced that the first patient has received study drug in a Phase 2 clinical study evaluating margetuximab in patients with metastatic breast cancer.  This study is designed to evaluate the activity of margetuximab in up to 41 patients with metastatic breast cancer whose tumors express a moderate level of the oncoprotein, HER2, represented by a 2+ score by immunohistochemistry.  These tumors must also lack evidence of HER2 gene amplification as determined by FISH testing.  The trial is being conducted at six sites across the United States.  For more information on the clinical trial, please see www.clinicaltrials.gov.

"To date, the results of our Phase 1 study are very encouraging and thus provide justification for advancing margetuximab into Phase 2 development," stated Scott Koenig , M.D., Ph.D., President and CEO of MacroGenics.  "While HER2 has proven to be an important target for several approved anti-cancer therapies, many patients are inadequately treated with existing therapies. Our next study will explore whether margetuximab can improve clinical outcomes in a sub-population of breast cancer patients, particularly those with low HER2 expression.  Additional studies with margetuximab in patients with HER2-expressing tumors other than breast cancer are anticipated."

About Breast Cancer and Margetuximab

The HER2 oncoprotein is over-expressed and plays an important role in tumorigenesis, tumor aggressiveness, and outcome in breast cancer and other solid tumors. HER2 has proven to be an excellent target for cancer therapeutics, given the success of currently marketed HER2-directed therapies. 

According to the National Cancer Institute, over 230,000 women in the U.S. are diagnosed with breast cancer annually.  Of these women, only about 20% have tumors that are HER2 positive (IHC 3+, or HER2 gene-amplified).  One development goal for margetuximab is to target a similarly large group of patients whose tumors exhibit HER2 expression that is less than 3+ and lack evidence of HER2 gene amplification and for whom current anti-HER2 therapies are not indicated.  Another goal for margetuximab is to determine if the Fc modifications will improve clinical outcomes in patients with tumors that are currently treated with other HER2 therapies, which would be consistent with results seen in laboratory models.

About MacroGenics, Inc.

MacroGenics is a leader in the discovery and development of innovative medicines that utilize its next-generation antibody-based technologies.  The company is advancing a pipeline of product candidates to treat patients with cancer and other serious, complex diseases.  MacroGenics' products and platforms have attracted multiple partnerships with leading pharmaceutical companies around the globe.  www.macrogenics.com

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law. 


'/>"/>
SOURCE MacroGenics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
2. Revolutionary Science Announces New Automatic and Manual Colony Counting Products
3. Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing
4. SoundConnect Announces Microsoft Lync Release in Canada
5. GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit
6. Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes
7. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
8. Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech
9. DNA Genotek Inc. Announces Spit for Africa Program
10. Metabolic Solutions Development Company announces publication of data describing a new drug target for diabetes
11. Discovery Labs Announces Completion of $14.25 Million Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back ... 8th June 2018 in San Francisco, CA. The Summit brings together current and former ... CEOs, board directors and government officials from around the world to address key issues ...
(Date:10/11/2017)... TX (PRWEB) , ... October 11, 2017 , ... ... August compared the implantation and pregnancy rates in frozen and fresh in ... contribution of progesterone and maternal age to IVF success. , After comparing the ...
(Date:10/10/2017)... Poway, California (PRWEB) , ... October 10, 2017 , ... ... afternoon speaking at his local San Diego Rotary Club. The event ... San Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017   Bridge Patient ... organizations, and MD EMR Systems , an ... partner for GE, have established a partnership to ... product and the GE Centricity™ products, including Centricity ... These new integrations will allow ...
(Date:4/18/2017)... -- Socionext Inc., a global expert in SoC-based imaging and computing solutions, ... which features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ... will be showcased during the upcoming Medtec Japan at Tokyo Big ... Las Vegas Convention Center April 24-27. ... Click here for an image of ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
Breaking Biology News(10 mins):